Last $147.75 USD
Change Today -1.68 / -1.12%
Volume 486.4K
PRGO On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
Frankfurt
As of 6:40 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Treasury Building

Lower Grand Canal Street

Dublin, 2

Ireland

Phone: 353 1 604 0031

Fax:

In addition, the Rx Pharmaceuticals segment offers OTC products through the prescription channel (referred to as ‘ORx’ that are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. The company offers approximately 100 ORx products that are reimbursable through various health plans and U.S. Medicaid and Medicare programs. The Rx Pharmaceuticals segment markets approximately 800 generic prescription and ORx products, with approximately 1,300 SKUs, to approximately 350 customers. The company’s U.S.-based customers are major wholesalers, including Cardinal Health, McKesson and AmerisourceBergen, as well as national and regional retail drug, supermarket and mass merchandise chains, including Walgreens, Walmart, CVS, Rite Aid, Kroger and Safeway. In 2014, the company launched new generic or authorized generic prescription products, including Fluticasone propionate lotion, Nitroglycerine spray, Repaglinide, Fenofibrate, Fluocinonide cream, Calcipotreine betamethasone dipropionate, and Desloratadine, which contain the same active ingredients present in the same dosage forms as Cutivate, Nitrolingual, Prandin, Tricor, Vanos, Taclonex, and Clarinex, respectively. In 2014, the company, on its own or in collaboration with partners, received final approval from the Food and Drug Administration (FDA) for 10 prescription drug applications. As of June 28, 2014, the company, on its own or in collaboration with partners, had 33 generic Rx drug applications pending approval with the FDA. Competition: The company’s competitors include Actavis; Apotex; Glenmark Generics Inc.; Impax; Mylan; Prasco; Sandoz; Taro Pharmaceuticals; Teva Pharmaceutical Industries Ltd.; Triax Pharmaceuticals; and Zydus Pharmaceuticals. API segment The API segment develops, manufactures and markets active pharmaceutical ingredients used worldwide by the generic drug industry and branded pharmaceutical companies. The API business identifies APIs critical to its pharmaceutical customers’ future product launches and then works closely with these customers on the development processes. API development is focused on the synthesis of less common molecules for the U.S., European and other international markets. Specialty Sciences segment The Specialty Sciences segment comprises primarily of assets focused on the treatment of Multiple Sclerosis (Tysabri). Competition: Tysabri competes primarily with Avonex, marketed by Biogen Idec; Betaseron, marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in the U.S. and sold under the name Betaferon by Bayer Schering Pharma in Europe; Rebif, marketed by Merck Serono and Pfizer in the U.S. and by Merck Serono in Europe; Copaxone marketed by Teva Neurosciences, Inc. in the U.S. and Europe; Novartis AG’s Gilenya, an oral treatment for relapsing MS; and Tecfidera, an oral agent marketed by Biogen Idec. Other The company has an Other category that includes Israel Pharmaceutical and Diagnostic Products. The Israel Pharmaceutical business includes the marketing and manufacturing of branded and generic prescription drugs under long-term exclusive licenses and the importation and distribution of pharmaceutical and other medical products into Israel based on exclusive agreements with the manufacturers. Research and development The company’s research and development spending was $152.5 million for 2014. Customers Walmart accounted for 19% of consolidated net sales for 2014. Seasonality Revenues in the company’s Consumer Healthcare segment are generally subject to the seasonal demands for cough/cold/flu products in its second and third quarters (year ended June 2014) and allergy products in its first and fourth quarters. In addition, the company's animal health products are subject to the seasonal demand for flea and tick products, which typically peaks during the warmer weather months. Regulations The manufacturing, processing, formulation, packaging, labeling, testing, storing, distributing, advertising and sale of the company’s products are subject to regulation b

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $147.75 USD -1.68

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $63.28 USD -0.53
Hospira Inc $54.74 USD -0.17
Mallinckrodt PLC $70.92 USD -1.25
Mead Johnson Nutrition Co $94.42 USD -0.06
Mylan Inc/PA $47.75 USD -0.84
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 84.1x
Price/Sales 4.9x
Price/Book 2.3x
Price/Cash Flow 97.4x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.